Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma.

Katsunori MatsushitaShogo KobayashiHirofumi AkitaMasamitsu KonnoAyumu AsaiTakehiro NodaYoshifumi IwagamiTadafumi AsaokaKunihito GotohMasaki MoriYuichiro DokiHidetoshi EguchiHideshi Ishii

Published in: Cancer reports (Hoboken, N.J.) (2021)

Our findings suggest that MYL9 is an independent prognostic factor of pancreatic ductal adenocarcinoma. MYL9 is a crucial biomarker and potential therapeutic target for pancreatic ductal adenocarcinoma.

Keyphrases

prognostic factors
poor prognosis
long non coding rna
risk assessment